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970Background: The objective of this study was to assess the safety of general thoracic surgery in patients taking
antiplatelet (clopidogrel) therapy.
Methods: A prospective study was conducted of consecutive patients who underwent general thoracic surgery
and who were taking clopidogrel perioperatively. They were matched using a propensity score from our prospec-
tive database of 11,768 patients. Intraoperative and postoperative outcomes were compared.
Results: Between January 2009 and April 2010 there were 33 patients on clopidogrel at the time of surgery and
132 controls. The most common procedures were thoracotomy with lobectomy in 11 patients (robotic in 1),
video-assisted wedge resection in 6, mediastinoscopy in 4, and Ivor Lewis esophagogastrectomy in 2. Epidurals
were not used. There was no intraoperative morbidity or bleeding in primary thoracotomy; however, 2 of the 4
patients who underwent redo thoracotomy had bleeding that required transfusions. None of the 8 patients receiv-
ing clopidogrel who had a coronary artery stent and underwent lobectomy had a perioperative myocardial infarc-
tion whereas 5 of the 14 control patients undergoing lobectomy who had a coronary artery stent did (P ¼ .05).
Otherwise, morbidity, mortality, and length of stay were no different.
Conclusions: Patients who are receiving clopidogrel and who have a coronary artery stent placed can safely
undergo general thoracic surgery. The widely held belief that surgery cannot be performed without bleeding is
untrue. This new finding not only eliminates much of the preoperative dilemma posed by these patients but
also may reduce their risk of a postoperative myocardial infarction. However, patients who require a redo thora-
cotomy may be at increased risk of bleeding. (J Thorac Cardiovasc Surg 2010;140:970-6)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Cardiovascular Surgwith ticlopidine, most cardiologists have used clopidogrel
(Plavix; Bristol-Myers Squibb/Sanofi-Aventis, New York,
NY), which selectively inhibits the binding of adenosine di-
phosphate to its platelet receptor and the subsequent adeno-
sine diphosphate–mediated activation of the glycoprotein
IIb–IIIa complex. This inhibits platelet aggregation.1 It rea-
ches its peak activity after 3 to 5 days and produces a pro-
longed antiplatelet effect of 7 to 10 days. Several reports
have shown the dramatically increased risk of coronary
thrombosis of up to 29% if clopidogrel is withdrawn prema-
turely.2 In fact, a sudden withdrawal of clopidogrel has been
shown to have a rebound effect with an increase in the hyper-
coagulation and prothrombotic state.2-5 The recent
recommendation from the American Heart Association’s
Science Advisory Committee is that patients who have
undergone placement of a drug-eluting coronary artery stent
should continue to receive dual antiplatelet therapy for at
least 12 months.6,7 These landmark recommendations have
changed the landscape of the preoperative management of
these patients all over the world. Many institutions held
emergency meetings between the heads of cardiology,
anesthesiology, and surgery to promulgate policy for these
patients. The result was a swirling morass of anxiety and
confusion. These rules mandated that no patients have their
clopidogrel stopped for 6 months if they had a sirolimus
stent placed in their coronary arteries, for 3 months if they
had a paclitaxel stent, or for 1 month if they had a bare
metal stent.8 Thus, patients with known malignant diseaseery c November 2010
Abbreviation and Acronym
IRB ¼ institutional review board
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required a coronary stent often received a bare metal stent,
followed by 1 month of clopidogrel and then surgery 1 or
2 weeks later to minimize the risk of bleeding. This therapy
compromised their coronary artery disease treatment with
perhaps a nonoptimal stent and simultaneously delayed their
cancer surgery for at least 6 weeks. In addition, it exposed
them to higher risk of a perioperative myocardial infarction.
Because of this complicated, volatile, and politically charged
situation, we decided to assess the safety of a less volatile and
simpler solution by operating on patients who were taking
clopidogrel and observing outcomes. In this study, we report
our initial results.
METHODS
This is a prospective study of a consecutive series of patients who re-
ceived clopidogrel up to and including the day of thoracic surgery as well
as each day postoperatively. These patients were matched 1:4 with patients
who were not receiving clopidogrel at the time of surgery using a propensity
score (greedy matching technique). All patients were 19 years of age or
older. Thirty-day major adverse cardiac events were recorded. A major ad-
verse cardiac event is defined as nonfatal myocardial infarction and/or car-
diac death as previously defined by the American College of Cardiology/
European Society of Cardiology.9 This study was approved by the Univer-
sity of Alabama at Birmingham Institutional Review Board (IRB). Individ-
ual consent for inclusion in the study was waived, but consent for inclusion
for our prospective database was obtained.
Any patient who was smoking cigarettes 2 weeks before the operation
was classified as a current smoker. The patient was defined as receiving pre-
operative chemotherapy only if it was related to lung cancer.
To reduce the influence of selection on the comparison of outcome, we
used propensity scores to match patients who were receiving clopidogrel at
the time of pulmonary resection to those that were not receiving clopidogrel
during pulmonary resection.10 The propensity-matched analysis is a balanc-
ing score method that attempts to correct bias in patient selection by creating
equivalent risk groups for analysis. Logistic regression analysis was used to
identify covariates among the baseline patient variables that were imbal-
anced between the 2 groups from which the model was derived. Variables
included age, gender, procedure type, history of coronary artery stent, dia-
betes, coronary artery disease, procedure type, and smoking history. Result-
ingmatched patients were analyzed for differences in selected intraoperative
and postoperative outcomes: operating time, estimated blood loss, hospital
length of stay, and 30-day operative morbidity and mortality. Statistical
models were analyzed using SAS (SAS Institute, Inc, Cary, NC). The c2
test was used to calculate the probability value for the comparison of dichot-
omous variables. Fisher’s exact test (2-sided) was used when the number in
any cell was less than 5. Values are expressed as the mean  SD unless
otherwise indicated.
RESULTS
There were 33 patients between January 2009 and April
2010 who were receiving clopidogrel at the time of general
thoracic surgery. Logistic regression analysis identified hav-
ing a cardiac stent, male gender, and history of cardiac dis-The Journal of Thoracic and Caease as predictors for being on a regimen of clopidogrel at
the time of surgery. This process matched 132 control pa-
tients from our prospective database out of the 11,768 in
it. Table 1 lists selected preoperative patient characteristics
between the 2 groups. There were no significant differences
between the 2 groups in age, history of coronary artery
disease, presence of a coronary stent, diabetes, peripheral
vascular disease, and preoperative Eastern Cooperative
Oncology Group score.
The indications for clopidogrel therapy at the time of sur-
gery were as follows: coronary artery stents in 21 patients,
history of myocardial infarction and/or coronary artery by-
pass graft and/or valve placement in 11 patients, and severe
peripheral vascular disease in 1 patient. The types of general
thoracic operations performed and the intraoperative and
postoperative outcomes are shown in Table 2. The 33 pa-
tients receiving clopidogrel have been subdivided into the
14 that were receiving both clopidogrel and aspirin together
at the time of surgery and the 19 patients who were receiving
clopidogrel alone. These were compared with the controls.
As shown, 7 of the 33 patients receiving clopidogrel had
postoperative morbidity, which was atrial fibrillation in 2 pa-
tients, postoperative bleeding requiring return to the operat-
ing room in 2, and pulmonary embolism, acute myocardial
infarction, and confusion in 1 each. None of the patients
who underwent primary thoracotomy required a reoperation
for bleeding or transfusion of blood or blood products. How-
ever, 2 of the 4 patients who underwent redo thoracotomy
had significant bleeding and both required transfusion of
packed red blood cells (4 and 5 units, respectively) and plate-
lets. Both of these patients were receiving clopidogrel and
aspirin. As shown in Figure 1, the amount of chest tube
drainage was statistically significantly higher in patients re-
ceiving clopidogrel for postoperative days 1 (P ¼ .026) and
2 (P ¼ .039) but not for postoperative day 3.
Table 3 provides a subanalysis of the patients who had
a coronary artery stent. It shows that there were 8 patients
in the clopidogrel group who had a lobectomy performed
and had a coronary artery stent, and none had a perioperative
myocardial infarction. This compares with the 14 control
patients who had a lobectomy performed and had a coronary
artery stent with 5 having a perioperative myocardial infarc-
tion and 2 dying (P ¼ .05). There was 1 operative death in
the clopidogrel group. This patient underwent an Ivor Lewis
esophagogastrectomy and had a postoperative myocardial in-
farction. There were 3 postoperative deaths in the control
group. All 3 of these patients underwent lobectomy; 2 patients
had a myocardial infarction and 1 had pulmonary emboli.
Table 4 details the patients who had major morbidity or
mortality. There were no statistically significant differences
between the outcomes for the 33 patients receiving clopi-
dogrel compared with the controls for operative time, hospi-
tal length of stay, estimated blood loss, or morbidity when
stratified by procedure.rdiovascular Surgery c Volume 140, Number 5 971
TABLE 1. Patient characteristics
Patients
receiving
clopidogrel
(n ¼ 33)
Matched patients
not receiving
clopidogrel
(n ¼ 132)
Age, y (mean)  SD (range) 67.5  9.7 (36–88) 66.8  9.2 (49–80)
Gender
Male 28 (87%) 96 (73%)
Female 5 (13%) 36 (27%)
Current cigarette smoker 15 (45%) 58 (44%)
History of coronary artery
disease
33 (100%) 132 (100%)
History of diabetes mellitus 7 (21%) 20 (15%)
History of peripheral vascular
disease
3 (9%) 5 (4%)
Coronary stent 21 (64%) 43 (33%)
Bare metal 2 4
Drug eluting stent 19 39
Median preoperative ECOG
score
1 1
Preoperative chemotherapy 4 (12%) 14 (11%)
Median length of time on
clopidogrel
5.2 mo (0.5 mo0.2 y) Not applicable
Patient on another form of
antiplatelet therapy*
7 (23%) 51 (39%)
SD, Standard deviation; ECOG, Eastern Cooperative Oncology Group. *Most patients
were receiving 81 mg of aspirin per day.
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A true clinical dilemma existed for surgeons once the Food
and Drug Administration convened a panel of experts in
December 2006 and published guidelines that recommendedTABLE 2. Comparison of intraoperative and postoperative outcomes
No. of patients on c
and aspirin (n
Initial procedure*
Lobectomy (open) 1
Lobectomy (robotic) 1
Mediastinoscopy 2
Bronchoscopy 1
Decortication 0
Ivor Lewis esophagogastrectomy 1
Chest wall resection 0
Sternotomy, resection of anterior mediastinal mass 0
VATS  wedge resection 5
Wedge resection 3
No. who returned to OR for bleeding/no. who underwent
primary thoracotomy and returned to OR for bleeding
0
No. who returned to OR for bleeding/no. who underwent
a redo thoracotomy
2/2
Average hospital length of stay, d (range) 2.0 (0–6)
Postoperative morbidity 4 (29%)
Postoperative MACE 0
Operative mortality 0
MACE, Major adverse cardiac event; VATS, video-assisted thoracoscopic surgery. *Som
recorded.
972 The Journal of Thoracic and Cardiovascular Surg12months of dual antiplatelet therapy for patients who under-
went placement of a coronary artery drug-eluting stent.11
Patients with cancer were not able to come to resection be-
cause of the widely documented risk of stopping these med-
icines prematurely12,13 However, this dilemma existed only
because of the assumption that surgery could not be safely
performed on patients who were receiving clopidogrel and
aspirin. Hence patients with non–small cell lung cancer
who had poor results on their preoperative stress test and
who required coronary artery stenting most commonly
received a bare metal stent. This type of stent, which often
compromised their coronary artery care, requires only 4 to
6 weeks of clopidogrel and aspirin therapy. Then these
patients would undergo pulmonary resection 7 to 10 days
after their dual antiplatelet therapy was discontinued. This
treatment strategy, while the standard of care at most
institutions, actually provided suboptimal care for both the
patient’s lung cancer (delay in treatment) and coronary
artery disease (inferior stent placed). There seemed to be no
optimal solution until the concept of operating on patients
who continued to receive clopidogrel was discussed.
Despite the paucity of literature to support the feasibility of
this approach, we were aware of surgeons besides cardiac
surgeons who had operated on some of these patients either
urgently or unknowingly with good results.
We tested our theory with extreme caution. We started
small with our first operation being a single-incision
video-assisted thoracoscopic drainage of a pleural effusion.
We had packed red blood cells and platelets ready in the op-
erating room. Surprisingly, the operative field appeared nolopidogrel
¼ 14)
No. of patients on clopidogrel
alone (n ¼ 19)
No. of patients in
control group (n ¼ 132)
10 45
0 2
2 16
1 8
1 3
1 8
2 8
1 4
1 26
0 12
0 0
0/4 1/12
3.0 (0–23) 4.1 (0–28)
3 (16%) 28 (21%)
1 (5%) 9 (7%)
1 (5%) 5 (3%)
e patients had multiple procedures/redo cases. Only the initial procedure has been
ery c November 2010
FIGURE 1. Average daily chest tube (CT) output (milliliters per day) in
patients who underwent lobectomy by study group. Patients receiving clo-
pidogrel had a significantly greater chest tube output on postoperative days
1 and 2.
TABLE 3. Comparisons of intraoperative and postoperative outcomes
for patients with coronary artery stents
Patients taking
clopidogrel who had
a coronary artery
stent (n ¼ 21)
Control patients
with a coronary
artery stent not taking
clopidogrel (n ¼ 43)
Initial procedure
Lobectomy (open) 7 14
Lobectomy (robotic) 1 0
Mediastinoscopy 1 5
Bronchoscopy 2 4
Decortication 0 0
Ivor Lewis 2 3
Chest wall resection 2 1
Sternotomy, resection
of anterior
mediastinal mass
0 1
VATS wedge wedge 3 10
Wedge resection 3 5
Postoperative morbidity 4 16 (37%)
Postoperative MACE 1 5 (13%)
Postoperative MACE for
patients who
underwent lobectomy
0/8 5/14 (36%)
p ¼ 0.05
Operative mortality 1 (5%) 3 (2%)
MACE, Major adverse cardiac event; VATS, video-assisted thoracoscopic surgery.
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dogrel and aspirin. We then slowly increased the degree of
invasiveness of the operations by performing the following:
video-assisted wedge resection for interstitial lung disease,
then a thoracotomy and lymph node dissection, then a lobec-
tomy, and finally a median sternotomy and resection of a 9-
cm thymic mass. Since then we have done 2 Ivor Lewis
esophagogastrectomies, a decortication, and a robotic lobec-
tomy. The operative field, although slightly less hemostatic
in some patients, was not dramatically different and in some
patients it seemed normal.
In this study we have shown that pulmonary resection (via
either a thoracotomy or robotic approach) and esophagogas-
trectomy can be performed safely in patients who are receiv-
ing both clopidogrel and aspirin. However, two caveats
should be noted. First, there appears to be a greater risk of
bleeding in patients who were receiving both clopidogrel
and aspirin and underwent a redo thoracotomy. This bleed-
ing was clinically significant. Thus now we recommend that
patients stop their aspirin and continue their clopidogrel
alone. Second, there was a statistically significantly in-
creased drainage in the clopidogrel group on postoperative
days 1 and 2. However, since we used less than 460 mL
per day as our criterion for chest tube removal, there was
no difference in duration of chest tube placement between
the 2 groups in our practice.14 Thus even for those surgeons
who use a more standard definition of less than 250 mL per
day before removal of chest tubes, there would be no differ-
ence in chest tube duration or hospital length of stay in pa-
tients who are receiving clopidogrel. Third, there may be
reduction of the incidence of perioperative myocardial in-
farction (as suggested by other literature with much larger
numbers of patients) of continuing the clopidogrel in
patients with coronary artery stents.The Journal of Thoracic and CaLung cancer remains the most common cause of cancer
death and coronary artery disease is the most common cause
of all deaths. With an aged population, more people will be
affected by both of these clinical problems. Many hospitals
have formalized centers for treatment of heart disease, which
has improved patient access to percutaneous coronary
interventions. Themost recent estimate by theCenters forDis-
easeControl and Preventionwas that 22.3% ofAmericans are
smokers. All of these factors together suggest a large number
of patients will have coronary stents placed and may need
a pulmonary resection. While the cardiologist wants to
provide the optimal coronary care and the thoracic surgeon
wants to provide the optimal oncologic care, our data suggest
that both can be accomplished at the same time.
There are several limitations to this study. First is the small
number of patients. However, inasmuch as it is an observa-
tional study, the conclusions are probably valid. Second is its
uni-institutional, nonrandomized design. Third, the propen-
sity scores rely on the ability to match from the population of
potential controls. Although our database is relatively large
and contains 11,000 patients, it may not be ideal.
In conclusion, we have shown that many types of general
thoracic surgical procedures can be safely performed in pa-
tients who are receiving clopidogrel and aspirin. There is no
increased risk of bleeding after primary thoracotomy or min-
imally invasive thoracic surgery. It addition, it should be
continued because it may offer a protective effect against
perioperative myocardial infarction, especially in thoserdiovascular Surgery c Volume 140, Number 5 973
TABLE 4. Patients taking clopidogrel who experienced postoperative bleeding, myocardial events, or operative mortality
Patient Procedure Taking aspirin Coronary stent Postop morbidity Operative mortality Reoperation for bleeding
1 Ivor Lewis No Yes Pulmonary embolism Yes No
2 Lobectomy Yes Yes Postop bleeding No Yes
3 Wedge Yes No Postop bleeding No Yes
4 Ivor Lewis Yes Yes Myocardial infarction No No
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platelet therapy. However, in those patients who are to un-
dergo a redo thoracotomy and who receive both
clopidogrel and aspirin, there is an increased risk of bleeding
secondary to the takedown of adhesions. It may be best in
these patients to stop their aspirin and have them continue
their clopidogrel alone. Further studies are needed.
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Dr David Park Mason (Cleveland, Ohio). I have no disclo-
sures. Dr Cerfolio, I enjoyed the talk and I enjoyed your paper
very much.
I do not think that it can be overstated that clopidogrel is a potent
inhibitor of coagulation, but also that you had excellent results, I
think, because you did excellent surgery and cautious surgery,
and not everyone is you. We have to think a little bit about the gen-
eralizability of the results. Careful and cautious surgery is obvi-
ously what you did, and the results are outstanding.
More and more patients are on a clopidogrel regimen, and many
for different reasons, when they are referred to us. Twenty-one of
your 33 patients were on it for coronary stents, and I think these
are the ones we worry about most. The others were on it for a smat-
tering of other reasons, such as peripheral vascular disease, for which
we do not worry as much. My question is, should we treat all clopi-
dogrel-treated patients the same? Are there some patients in whom it
would not be so worrisome to consider stopping clopidogrel?
Dr Cerfolio. I think if you have a patient who has been pre-
scribed clopidogrel because he had a clot in his toenail in 1972,
which we see all the time, and there is no reason why he is on it
and it’s a redo, I would take the patient off and decrease my risk,
However, if the patient is on it for a good reason, such as a recently
deployed stent with significant coronary artery disease, especially
a drug-eluting stent, I would keep him on it but stop the aspirin if
the operation was a redo. If it was a primary thoracotomy, I would
continue both.
DrMason.My second question has to do with the heterogeneity
of your population. You did many different cases, and for that rea-
son you actually gained a lot of experience in operating on these pa-
tients who were receiving clopidogrel. You mentioned that the only
operations you would hesitate to perform in the future are the redo
thoracotomies. Are there any other operations that you would say, I
do not think that’s a good idea. I saw this. I learned something from
this that I would recommend to my surgeons in the future.
Dr Cerfolio. That is a great question. I would counter your first
part by saying that if I can do it, everybody in this room can do it,
because I am probably not going as slowly as I should. In doing the
redo, the surgeon really has to slow down and take those adhesions
down quickly. You cannot put your hand in there and tear stuff.
You have to use the Bovie device. But I think mediastinoscopy
was what I worried about the most. I had to use Surgicel hemostats
(Ethicon, Inc, Somerville, NJ) on a couple of those patients. They
did not bleed or need transfusions, but I think you need to be very
careful with that. If you are going to do a mediastinoscopy, just
make sure that the patient needs to be on the clopidogrel regimen.
I do still think it is safe.
Dr Sandro Mattioli (Bologna, Italy). That is an interesting
issue. In Italy we have launched a multicenter study with 7 veryery c November 2010
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ford this only on an observational basis. The point is that we do not
know how frequent this problem is. I do not understand your re-
cruitment. Did you get your patients with and without double med-
ical therapy in sequence or were they historical cases? So the first
question is frequency, because if this is frequent, we can talk to
the cardiologists; otherwise, they will ignore us.
Dr Cerfolio. This is a consecutive series. Once we said we were
going to follow this program, we applied it to everyone who was
referred to us. By contrast, in the patients whom we treated earlier,
I was stopping clopidogrel because I did not think I could operate
on them while they were receiving it.
Dr Joseph B. Shrager (Stanford, Calif). Rob, the data are not
very granular. It is back to the operating room or not back to the op-
erating room or transfusion or no transfusion. Do you have no chest
tube output data?Maybe if you got a little more granular you would
see differences.
Dr Cerfolio.Yes, we do. That information is in the paper. How-
ever, these patients bled significantly intraoperatively and postop-
eratively. One patient lost 1000 mL and I think the other lost
1400 mL.
Dr David J. Sugarbaker (Boston, Mass). Given the degree of
equipoise as to whether or not you should leave them on their clo-
pidogrel and operate or take them off their clopidogrel and run the
risk of having a coronary event, did you consider a prospective
randomized trial following an IRB approach?
Dr Cerfolio. No, because I wanted to show safety first. This
would be the benchmark to go to that trial.
Dr Sugarbaker. I see. It does not seem like it would have
enough power to draw any conclusions regarding safety, but I
will defer to the statisticians.
Dr Bryan F. Meyers (St Louis, Mo). I think this is a useful and
practical study and I thank you for doing it.
If you look at retrospective case series, when people had stopped
the clopidogrel in patients with stents and operated on them, what
you learn is that there is a 10% myocardial infarction rate, and
among those that have an infarction, there is about a 50% death
rate. This is a substantial problem in that group of patients. I would
like to point out an interesting thing that came out talking to our car-
diologists. The reason that the 6-month number exists—when they
talk about using clopidogrel for 6 months—is that in some of the
early stent trials, the company that makes clopidogrel offered 6
months of free clopidogrel. The end point of that time is not evi-
dence-based at all, so you might as well just keep continuing it.
Did you limit this to just patients who had had stents within 6
months?
Dr Cerfolio. No, we did a consecutive series of patients who
came to us on a clopidogrel rgimen and operated on them.
DrMeyers.You operated on anybody on clopidogrel regardless
of how long it was before their cardiac intervention?
Dr Cerfolio. Yes, sir.
Dr Meyers. That’s good.
Dr Scott I. Reznik (Temple, Tex). Inasmuch as the American
Association of Anesthesiologists will prevent placement of an epi-
dural with recent clopidogrel use, did you see any more respiratory
embarrassment or more atelectasis or even more pain?
Dr Cerfolio. Good question. None of these patients got an epi-
dural because I certainly did not want to have that conversation.The Journal of Thoracic and CaThey all got an on-Q pain pump, and we did not notice the differ-
ence, but, again, it was a small number of patients.
Dr Ayman Abdul-Ghani (Anniston, Ala). I enjoyed your talk,
Dr Cerfolio.
Back when I used to do cardiac surgery in Liverpool, I tried to do
a study on taking down the mammary while the patient was receiv-
ing clopidogrel. We had to stop it after 10 or 15 cases, not because
of take-back for bleeding but because of chest tube output. We used
to transfuse that amount back into the patient. Have you considered
putting the patients on a regimen of enoxaparin sodium (Lovenox)?
I have done it on 1 or 2 patients, stopping the clopidogrel, using
enoxaparin sodium at home, with the approval of the cardiologist,
stopping it before surgery, and starting clopidogrel immediately af-
ter surgery.
Dr Cerfolio. That is one of the compromises that we were doing
in the past, but it is still a compromise. The anesthesia and cardiol-
ogy data are very clear. If you stop that clopidogrel, you are risking
a lawsuit with much higher risk of perioperative myocardial infarc-
tion. So I do not think that is the solution. That is not going to make
people happy. And the cost of enoxaparin sodium at home is
through the roof. You could do that, but I do not think that is
a good solution.
Dr Daniel C. Wiener (Boston, Mass). There is some literature
indicating that about 20% of patients are nonresponders to clopi-
dogrel. I wonder whether, in that small number, some of the results
are skewed by the fact that some of those patients may actually be
nonresponders, and how can that be addressed?
Dr Cerfolio. That is a great question and one that we cannot an-
swer. Some of these patients did not seem to bleed any more than
patients who were not receiving clopidogrel. That may be right,
but I cannot answer that.
Dr Gunda Leschber (Berlin, Germany). I think you mentioned
that you did a decortication as well on clopidogrel. Could you com-
ment on this?
Dr Cerfolio. Yes. That really was risky. That was done on a pa-
tient in the hospital whomwe took and did that the next day.We did
okay, but we were doing a pleurectomy, a visceral pleurectomy,
and I usually do a parietal pleurectomy. We went slowly and we
were smart and did okay.
Dr Shrager. You had IRB approval to do this?
Dr Cerfolio.We had to inform the IRB just that we were going
to try this to start.
Dr Shrager. You had IRB approval?
Dr Cerfolio.Yes.We just told the IRBwe were going to do this.
Dr Shrager. Did they say you were exempted from whatever?
Dr Cerfolio. No, no. They did not say we had to do anything
fancy. They did not say that we needed to go through committees
or boards. We went to anesthesia, went to cardiology, told the
IRB we were going to try to operate on clopidogrel, and we got
it in as just the safety trial.
Dr Sugarbaker. So you did not have to do an informed consent?
Dr Cerfolio. Yes, we had to do an informed consent, but we did
an expedited thing. We did not need to go through the typical IRB
that takes us forever.
Dr Shekar Reddy (Durham, NC). It was rather surprising to
hear that your patients did not bleed at all, and that ties in with
the previous question about the nonresponders. In your future
work, if you add a thromboelastogram to these patients asrdiovascular Surgery c Volume 140, Number 5 975
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Sa preoperative control, you will have muchmore robust and reliable
data to prove that they have been on antiplatelets and the extent to
which those drugs have been useful. If you can tie that in with your
outputs, I think you will have a much more robust experimental
design in the future.976 The Journal of Thoracic and Cardiovascular SurgDr Cerfolio. As a scientist that is good, but as a clinician, if the
patients do not bleed, I am thrilled. I do not care why they are not
bleeding; they ain’t bleeding. For me, the idea that all 33 were not
responders is unlikely. I take your comment, but I want you to listen
to my response.ery c November 2010
